Elucidating the exact pharmacological system of action (MOA) of naturally happening compounds is often demanding. Whilst Tarselli et al. (sixty) designed the primary de novo synthetic pathway to conolidine and showcased that this naturally occurring compound successfully suppresses responses to both chemically induced and inflammation-derived pain,